45th Annual Meeting of the American Society of Hematology December 6-9, 2003 San Diego, California

Clinical Lymphoma

Volumn 4, Issue 4, 2004, Pages 206-212

  Gibson, Angelia ^a   Klem, Jennifer ^a   Price, Nancy ^a   Reddy, G Kesava ^a   Jain, Vinay K ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; ASCORBIC ACID; BORTEZOMIB; CARBOPLATIN; CD20 ANTIGEN; CD38 ANTIGEN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; ETOPOSIDE; GLUTATHIONE TRANSFERASE; IFOSFAMIDE; IMMUNOGLOBULIN HEAVY CHAIN; LACTATE DEHYDROGENASE; LENALIDOMIDE; MELPHALAN; PREDNISONE; PROTEIN KINASE SYK; PROTEIN KINASE ZAP 70; RITUXIMAB; THALIDOMIDE DERIVATIVE; VINCRISTINE;

ADULT; ANEMIA; ANTIGEN EXPRESSION; BONE MARROW SUPPRESSION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; CORRELATION ANALYSIS; DEEP VEIN THROMBOSIS; DISEASE COURSE; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG SAFETY; FATIGUE; FOLLOW UP; GENE EXPRESSION PROFILING; GENE MUTATION; GENE OVEREXPRESSION; HEMATOLOGY; HODGKIN DISEASE; HUMAN; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; INFECTION; KIDNEY DISEASE; LIVER DISEASE; LUNG EDEMA; LYMPHOCYTE COUNT; MEDICAL SOCIETY; MULTIPLE MYELOMA; NEUROPATHY; NEUTROPENIA; NONHODGKIN LYMPHOMA; OXIDATIVE STRESS; PERIPHERAL EDEMA; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FAMILY; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTOR; SIGNAL TRANSDUCTION; SOMATIC HYPERMUTATION; SOMNOLENCE; STEM CELL TRANSPLANTATION; TERATOGENICITY; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; UNITED STATES;

EID: 1942531993     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1526-9655(11)70034-3     Document Type: Conference Paper

References (38)

1. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:235-242.
2. Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17:268-276.
3. Czuczman MS, Grillo-Lopez AJ, LoBuglio AI, et al. Patients with low-grade NHL treated with rituximab + CHOP experience prolonged clinical and molecular remission. Blood 2003; 102(suppl):411a (Abstract #1493).
4. Marcus R, Imrie K, Belch AR, et al. An international multi-centre, randomized, open-label, phase III trial comparing rituximab added to CVP chemotherapy to CVP chemotherapy alone in untreated stage III/IV follicular non-hodgkin's lymphoma. Blood 2003; 102(suppl):28a (Abstract #87).
5. Singhal S, Mehra J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341:1565-1571.
6. Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98:492-494.
7. Anderson KC. Moving disease biology from the laboratory to the clinic. Semin Oncol 2002; 29:17-20.
8. Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002; 100:3063-3067.
9. Richardson P, Jagannath S, Schlossman R, et al. A multi-center, randomized phase II study to evaluate the efficacy and safety of 2 CDC-5013 dose regimens when used alone or in combination with dexamethasone (dex) for the treatment of relapsed or refractory multiple myeloma (MM). Blood 2003; 102(suppl):235a (Abstract #825).
10. Soignet SL, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998; 339:1341-1348.
11. Soignet SL, Frankel SR, Douer D, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001; 19:3852-3860.
12. Lazo G, Kantarjian H, Estey E, et al. Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience. Cancer 2003; 97:2218-2224.
13. Shi Z, Shen Z, Fang, J, et al. Induction/maintenance with ATRA/ As2O3 combination yeilds a high quality clinical/molecular remission and disease-free survival in newly diagnosed patients with acute promyelocytic leukemia. Blood 2003; 102(suppl):141a (Abstract #486).
14. Jing Y, Dai J, Chalmers-Redman RM, et al. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 1999; 94:2102-2111.
15. Jia F, Chen G, Huang X, et al. Arsenic trioxide induces multiple myeloma cell apoptosis via disruption of mitochondrial transmembrane potentials and activation of caspase-3. Chin Med J (Engl) 2001; 114:19-24.
16. Liu Q, Hilsenbeck S, Gazitt Y. Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL. Blood 2003; 101:4078-4087.
17. Deaglio S, Canella D, Baj G, et al. Evidence of an immunologic mechanism behind the therapeutical effects of arsenic trioxide (As(2)O(3)) on myeloma cells. Leuk Res 2001; 25:227-235.
18. Munshi NC, Tricot G, Desikan R, et al. Clinical activity of arsenic trioxide for the treatment of multiple myeloma. Leukemia 2002; 16:1835-1837.
19. Bahlis NJ, McCafferty-Grad J, Jordan-McMurry I, et al. Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin Cancer Res 2002; 8:3658-3668.
20. Grad JM, Bahlis NJ, Reis I, et al. Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood 2001; 98:805-813.
21. Borad MS, Swift RA, Sadler K, et al. Melphalan, arsenic trioxide and ascorbic acid (MAC) is effective in the treatment of refractory and relapsed multiple myeloma (MM). Blood 2003; 102(suppl):235a (Abstract #827).
22. Oken MM, Harrington DP, Abramson N, et al. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479. Cancer 1997; 79:1561-1567.
23. Gustavsson A, Osterman B, Cavallin-Stahl E. A systematic overview of radiation therapy effects in Hodgkin's lymphoma. Acta Oncol 2003; 42:589-604.
24. Moskowitz C, Nimer SD. Autologous Transplantation for Hodgkin's Disease: Who Benefits? In: Bowell B, ed. Current Controversies in Bone Marrow Transplantation. Totowa, NJ: Humana Press, 2000:137-147.
25. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993; 341:1051-1054.
26. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002; 359:2065-2071.
27. Moskowitz C. Risk-adapted therapy for relapsed and refractory lymphoma using ICE chemotherapy. Cancer Chemother Pharmacol 2002; 49(suppl 1):S9-S12.
28. Moskowitz C. Management of Aggressive Relapsed Lymphoma. Presented at: Current Trends in Leukemia, Lymphoma, and Myeloma: A Post-ASH Update; January 10, 2004; New York, NY.
29. Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46:219-234.
30. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48:198-206.
31. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94:1840-1847.
32. Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001; 194:1639-1647.
33. Latour S, Veillette A. Proximal protein tyrosine kinases in immunoreceptor signaling. Curr Opin Immunol 2001; 13:299-306.
34. Orchard JA, Davis Z, Ibbotson RE, et al. Comparison of ZAP-70, IgVH gene mutational status and CD38 in CLL patients requiring therapy: preliminary report from the UK CLL IV trial. Blood 2003; 102(suppl):33a (Abstract #105).
35. Orchard JA, Ibbotson RE, Davis Z, et al. ZAP-70, expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004; 363:105-111.
36. Kowal M, Dmoszynska A, Bojarska-Junak A, et al. Prognostic significance of Zap-70 expression in B-cell chronic lymphocytic leukemia (CLL). Blood 2003; 102(suppl): 349b (Abstract #5123).
37. Del Poeta G, Gattei V, Del Principe MI, et al. Zap-70 protein tyrosine kinase is a powerful prognostic indicator in B-cell chronic lymphocytic leukemia (B-CLL). Blood 2003; 102(suppl):666a (Abstract #2466).
38. Wiestner A, Rosenwald A, Barry TS, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003; 101:4944-4951.